Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats

Journal of Nutrition

Volumn 141, Issue 6, 2011, Pages 1062-1069

  Panchal, Sunil K ^a,b   Poudyal, Hemant ^b   Arumugam, Thiruma V ^b   Brown, Lindsay ^a,b  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; CARBOHYDRATE; DRINKING WATER; FAT; FRUCTOSE; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RUTOSIDE; STARCH;

ABDOMINAL FAT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL STIFFNESS; ARTICLE; ATTENUATION; BEEF; BLOOD; BLOOD SAMPLING; CARBOHYDRATE DIET; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; FEEDING; FLUID INTAKE; FOOD INTAKE; GLUCOSE TOLERANCE; HEART; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY INFILTRATE; LIPID DIET; LIVER; LIVER FUNCTION; MALE; METABOLIC RATE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; RAT; TREATMENT DURATION;

ANIMALS; APOPTOSIS; CASPASE 3; DIETARY CARBOHYDRATES; DIETARY FATS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY LIVER; HSP70 HEAT-SHOCK PROTEINS; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; RATS; RATS, WISTAR; RUTIN; VENTRICULAR REMODELING;

RATTUS; ZEA MAYS;

EID: 79958211266     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.137877     Document Type: Article

References (59)

1. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev. 1998;56:317-33.
2. Benavente-Garcîa O, Castillo J. Updates on uses and properties of Citrus flavonoids: new findings in anticancer, cardiovascular, and antiinflammatory activity. Agric Food Chem. 2008;56:6185-205.
3. Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Muller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by polipoprotein E genotype. J Nutr. 2010;140:278-84.
4. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker ats. Obesity (Silver Spring). 2008;16:2081-7.
5. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes. 2009;58:2198-210.
6. Kamalakkannan N, Stanely Mainzen Prince P. Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues. Mol Cell Biochem. 006;293:211-9.
7. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059-62.
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-31.
9. Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol. 2010;105:2093-102.
10. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam A, Diwan V, Kauter K, Sernia C, Campbell F, et al. High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol. 2011;57:51-64.
11. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern taly. Ann Intern Med. 2000;132:112-7.
12. Bell LN, Lee L, Saxena R, Bemis KG, Wang M, Theodorakis JL, Vuppalanchi R, Alloosh M, Sturek M, et al. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol. 2010;298: G746-54.
13. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40: 949-55.
14. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis. 2009;19:646-53.
15. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;55:560-78.
16. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17 Suppl:S186-90.
17. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679-89.
18. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125-49.
19. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 010;52:727-36.
20. Choi I, Park Y, Choi H, Lee EH. Anti-adipogenic activity of rutin in 3T3-L1 cells and mice fed with high-fat diet. Biofactors. 2006; 26:273-81.
21. Kamalakkannan N, Prince PS. Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic flavonoid, in streptozotocin-induced diabetic Wistar rats. asic Clin Pharmacol Toxicol. 2006;98:97-103.
22. Stanley Mainzen Prince P, Kamalakkannan N. Rutin improves glucose homeostasis in streptozotocin diabetic tissues by altering glycolytic and gluconeogenic nzymes. J Biochem Mol Toxicol. 2006;20:96-102.
23. Krishna KM, Annapurna A, Gopal GS, Chalam CR, Madan K, Kumar VK, Prakash GJ. Partial reversal by rutin and quercetin of impaired cardiac function in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol. 2005;83:343-55.
24. Karthick M, Stanely Mainzen Prince P. Preventive effect of rutin, a bioflavonoid, on lipid peroxides and antioxidants in isoproterenolinduced myocardial nfarction in rats. J Pharm Pharmacol. 2006;58:701-7.
25. Janbaz KH, Saeed SA, Gilani AH. Protective effect of rutin on paracetamol- and CCl4-induced hepatotoxicity in rodents. Fitoterapia. 2002;73:557-63.
26. Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 010;140:946-53.
27. Poudyal H, Panchal S, Brown L. Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic yndrome. Br J Nutr. 2010;104:1322-32.
28. Sim AS, Salonikas C, Naidoo D, Wilcken DE. Improved method for plasmamalondialdehydemeasurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785:337-44.
29. Lexis LA, Fenning A, Brown L, Fassett RG, Coombes JS. Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-nduced vascular dysfunction. Am J Transplant. 2006; 6:41-9.
30. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203.
31. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-40.
32. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288:2709-16.
33. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic yndrome. Diabetes Care. 2001;24:683-9.
34. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705-12.
35. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients ith metabolic syndrome. J Nutr. 2006;136:3022-6.
36. Marsland AL, McCaffery JM, Muldoon MF, Manuck SB. Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. etabolism. 2010;59:1801-8.
37. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007;22:659-61.
38. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:S2073-85.
39. Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs. 992;44:1013-32.
40. Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, Ippolito E, Di Renzo A, Dugall M, et al. 5-year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(β-hydroxyethyl)-rutosides: a prospective comparative clinical registry. ngiology. 2008;59:S14-20.
41. Lund F, Qian Z, Schiötz J, Tillgren C. Limb salvage instead of amputation in 10 cases of nonreconstructible "end-point ischemia" treated with i.v. hydroxyethylrutosides plus oral anticoagulation. Angiology. 2002;53:391-8.
42. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002;58:395-402.
43. Zhang G, Hamakar BR. Slowly digestible starch: concept, mechanism, and proposed extended glycemic index. Crit Rev Food Sci Nutr. 2009;49:852-67.
44. Thirunavukkarasu V, Nandini A, Anuradha CV. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high ructose fed-rats. J Comp Physiol B. 2004;174:587-92.
45. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol. 2008;24:204-9.
46. Tappy L, LêKA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23-46.
47. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 004;79:537-43.
48. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282:22678-88.
49. Hu YB, Liu XY. Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scand J Gastroenterol. 2009; 44:1356-62.
50. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 010;42:320-30.
51. Kauss T, Moynet D, Rambert J, Al-Kharrat A, Brajot S, Thiolat D, Ennemany R, Fawaz F, Mossalayi MD. Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis. Arthritis Res Ther. 2008;10:R19.
52. Guardia T, Rotelli AE, Juarez AO, Pelzer LE. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis n rat. Farmaco. 2001;56:683-7.
53. Ziaee A, Zamansoltani F, Nassiri-Asl M, Abbasi E. Effects of rutin on lipid profile in hypercholesterolaemic rats. Basic Clin Pharmacol Toxicol. 2009;104:253-8.
54. Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, Cefalu WT, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008; 57:S39-46.
55. Rotelli AE, Guardia T, Juarez AO, de la Rocha NE, Pelzer LE. Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res. 003;48:601-6.
56. Kim H, Kong H, Choi B, Yang Y, Kim Y, Lim MJ, Neckers L, Jung Y. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res. 2005;22:1499-509.
57. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens. 2010;28:2111-9.
58. Gkaliagkousi E, Douma S, Zamboulis C, Ferro A. Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens. 009;27:2310-20.
59. Thomas SR, Chen K, Keaney JF Jr. Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redox Signal. 2003;5:181-94.